What is King Pharmaceuticals's additional paid-in capital?

King Pharmaceuticals (KG) reported additional paid-in capital of $178.98M in Q1 2026.

What does additional paid-in capital mean?

Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.

King Pharmaceuticals KG Additional Paid-In Capital

Additional Paid-In Capital at other companies

Arch Capital GroupACGL

$2.83B+9.4%

Everest GroupEG

$3.85B+1.3%

SiriusPointSPNT

$956.4M+1.2%

KKR & Co.KKR

$18.98B+2.0%

Skyward Specialty Insurance Group, Inc.SKWD

$922.31M+27.9%

Tiptree Inc.TIPT

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's additional paid-in capital?: King Pharmaceuticals (KG) reported additional paid-in capital of $178.98M in Q1 2026.
What does additional paid-in capital mean?: Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.